CD276 and cancer: An unexpected discovery that emerged while testing the sensitivity of a panel of cancer cell lines, all with similar CD276 levels, was that cancer sensitivity to m276-SL-PBD depended not only on the presence of target, but also on the cancer type (Figures 4A-4F).